Crossref
Regeneron Wins FDA Approval for First Neurosensory Gene Therapy
Human Gene Therapy · 01.07.2026 · 37 (13-14) · 547-550
DOI: 10.1177/10430342261454500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, online erschienen am 24.05.2026. Verfasst von Alex Philippidis. Beteiligte Einrichtung: Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA.
Zitieren
APA
Philippidis, A. (2026). Regeneron Wins FDA Approval for First Neurosensory Gene Therapy. Human Gene Therapy, 37(13-14), 547-550. https://doi.org/10.1177/10430342261454500
Vancouver
Philippidis A. Regeneron Wins FDA Approval for First Neurosensory Gene Therapy. Human Gene Therapy. 2026;37(13-14):547-550. doi:10.1177/10430342261454500
BibTeX
@article{Philippidis2026,
author = {Philippidis, Alex},
title = {Regeneron Wins FDA Approval for First Neurosensory Gene Therapy},
journal = {Human Gene Therapy},
year = {2026},
volume = {37},
number = {13-14},
pages = {547--550},
doi = {10.1177/10430342261454500}
}
EUVIMED